Syndax Pharmaceuticals Inc

Ticker SNDX

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

51-200 Employees
Based in Waltham, Massachusetts

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Company lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human…More

Visit website

REPORT RATINGS

4.8 / 5.0 (188)

Syndax Pharmaceuticals Inc reports have an aggregate usefulness score of 4.8 based on 188 reviews.

Syndax Pharmaceuticals Inc

Most Recent Annual Report

MOST RECENT 2024 Annual Report and Form 10K

View PDF View Form 10K (HTML)

Syndax Pharmaceuticals Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.